Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676185 | 0.84 | HTT (0.61) | CA2DYRK1AAPPMAPTHTT | |
| 2-Mercaptobenzothiazole SCHEMBL2170236 | 0.82 | MAPT (0.49) | CA2DYRK1AAPPRAB9AKDM4E | |
| SCHEMBL28090972 | 0.79 | CA2 (0.56) | CA2DYRK1AAPPRAB9AKDM4E | |
| SCHEMBL1094971 | 0.79 | NPC1 (0.35) | CA2DYRK1ARAB9AKDM4EMAPT | |
| Isobutane SCHEMBL8357971 | 0.78 | HTT (0.54) | CA2DYRK1AAPPMAPTHTT | |
| SCHEMBL28052498 | 0.78 | NPC1 (0.34) | CA2DYRK1ARAB9AKDM4EMAPT | |
| SCHEMBL72699 | 0.76 | GAA (0.72) | CA2DYRK1AAPPRAB9AKDM4E | |
| SCHEMBL27987130 | 0.76 | CA2 (0.53) | CA2DYRK1AAPPRAB9AKDM4E | |
| SCHEMBL21412413 | 0.76 | CA2 (0.53) | CA2DYRK1AAPPRAB9AKDM4E | |
| SCHEMBL30106441 | 0.76 | SMN1; SMN2 (0.61) | CA2DYRK1AAPPRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105734587-A | Novel macro-molecular corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| US-4021248-A | SILVER HALIDE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-05-03 | — | — | US | claimed |
| CN-107829094-B | High temperature resistant corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-105734587-A | Novel macro-molecular corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| WO-2014144878-A2 | NOVEL THIOL & AMINO MODIFYING REAGENTS FOR PROTEIN CHEMISTRY AND METHODS OF USE THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144878-A2 | NOVEL THIOL & AMINO MODIFYING REAGENTS FOR PROTEIN CHEMISTRY AND METHODS OF USE THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2211862-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050228-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050228-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | CA2 1118/4885DYRK1A 1640/4885APP 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.